New codes for these technologies have made a world of difference for clinicians. Reimbursement for the use of AI is an area where cardiology is far ahead of most other healthcare specialties.
The law reflects growing interest in using existing imaging studies to identify cardiovascular disease risk without requiring additional scans, radiation exposure or costs.
"We really should have a system that is patient-centric, physician-led, and professionally managed, but in a cost-effective way," Rick Snyder, MD, said.
MRI scans have traditionally been used for extracellular volume assessments. That is starting to change, however, as cardiac CT moves beyond its typical focus on the coronary arteries.
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
J.D. Corl, MD, shared his experience using two new IVL catheters from Shockwave Medical to treat patients with heavily calcified peripheral arteries. He considers both new devices a significant upgrade.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.
